Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics

Cantor Fitzgerald has officially commenced coverage on shares of Aquestive Therapeutics, as stated in a report released on Tuesday. The investment firm has rated the stock as "overweight" and set a target price of $17.00. This target suggests a significant potential upside of 372.22% when compared to the stock's previous closing price.

In addition to Cantor Fitzgerald's report, other analysts have also recently evaluated the company. For instance, Leerink Partners raised their price objective for Aquestive Therapeutics shares from $12.00 to $13.00, assigning an "outperform" rating in a report dated October 25. Meanwhile, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on November 6. JMP Securities also maintained a "market outperform" rating with a price objective of $9.00 on October 8. Currently, six analysts have given the stock a buy rating, and one has issued a strong buy rating. Based on data from MarketBeat, the consensus rating for Aquestive Therapeutics is "Buy," with an average target price of $11.00.

Aquestive Therapeutics Stock Performance

As of Tuesday, shares of Aquestive Therapeutics opened at $3.60. The stock has seen a 12-month low of $1.84 and a high of $6.23. The company's 50-day moving average price stands at $4.83, while the 200-day moving average is at $4.06. Currently, the firm's market capitalization is approximately $328.24 million, with a price-to-earnings ratio of -8.00 and a beta of 2.62.

Recent Earnings Report

Aquestive Therapeutics announced its latest quarterly earnings on November 4. For the period, the company reported earnings per share (EPS) of ($0.13), which was below analysts' consensus estimate of ($0.12) by $0.01. The reported revenue for the quarter was $13.54 million, exceeding the expected $12.69 million. In the same quarter the previous year, the business reported an EPS of ($0.03). Analysts anticipate that the company will report an EPS of -0.47 for the current fiscal year.

Investment Activity

In terms of institutional ownership, several hedge funds have recently adjusted their holdings in Aquestive Therapeutics. For example, State Street Corp increased its stake by 52.1% during the third quarter, now holding 1,496,739 shares valued at $7,454,000 after acquiring an additional 512,682 shares. Meanwhile, Blue Owl Capital Holdings LP raised its holdings by 30.3% in the second quarter, owning 1,140,000 shares worth $2,964,000 after buying an extra 265,000 shares. Other institutional investors, including the Bank of New York Mellon Corp and Wellington Management Group LLP, have also taken positions in the company. Overall, hedge funds and institutional investors collectively own approximately 32.45% of the stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company both in the United States and internationally. The company is known for marketing several products, including Sympazan, which is an oral soluble film formulation of clobazam for treating Lennox-Gastaut syndrome; Suboxone, a sublingual film formulation for opioid dependence; Zuplenz, a film formulation for nausea and vomiting; and Azstarys, a once-daily treatment for attention deficit hyperactivity disorder.

Cantor, coverage, stocks, analysis, investment